Caprock Announces Closing of Private Placement

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.

Newsfile Corp • Jun 19, 2026

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.

Newsfile Corp • Jun 17, 2026

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m.

Newsfile Corp • Jun 12, 2026

Caprock Announces Proposed Private Placement

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering.

Newsfile Corp • Jun 12, 2026

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.

MarketBeat • Jun 11, 2026

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.

GlobeNewsWire • Jun 8, 2026

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac endpoints, reducing trial-related risks. Key remaining risks include commercial disputes with NS Pharma/Nippon Shinyaku and limited initial manufacturing capacity.

Seeking Alpha • Jun 3, 2026

Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku.

MarketBeat • May 12, 2026

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026